| upifitamab rilsodotin (XMT-1536) / Mersana |
| Terminated | 3 | 20 | Canada, US, RoW | Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo | Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) | High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 09/23 | 09/23 | | |
2021-005099-21: Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) |
|
|
| Not yet recruiting | 3 | 581 | Europe | Upifitamab rilsodotin, XMT-1536, Powder for solution for infusion | Mersana Therapeutics, Inc., Mersana Therapeutics Inc, Mersana Therapeutics, Inc., Mersana Therapeutics, Inc | Recurrent, Platinum-Sensitive Ovarian Cancer, Ovarian cancer, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 1/2 | 523 | US | upifitamab rilsodotin, XMT-1536, UpRi | Mersana Therapeutics | Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic | 05/23 | 10/24 | | |
NCT06517433: First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b |
|
|
| Completed | 1 | 62 | US | upifitamab rilsodotin, XMT-1536, UpRi | Mersana Therapeutics | Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic | 07/21 | 07/21 | | |
NCT06517485: First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b |
|
|
| Completed | 1 | 142 | US | upifitamab rilsodotin, XMT-1536, UpRi | Mersana Therapeutics | Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma | 05/22 | 08/22 | | |
UPGRADE, NCT04907968: Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer |
|
|
| Terminated | 1 | 31 | US | XMT-1536 (Upifitamab Rilsodotin), XMT-1536, UpRi, Carboplatin | Mersana Therapeutics, IQVIA Biotech, PSI CRO | Platinum-sensitive Ovarian Cancer (UPGRADE-A) | 10/23 | 10/23 | | |
| XMT-1592 / Mersana |
NCT04396340: First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b |
|
|
| Terminated | 1 | 31 | US | XMT-1592 | Mersana Therapeutics, IQVIA Biotech | Ovarian Cancer, Nonsmall Cell Lung Cancer | 09/22 | 09/22 | | |
| calotatug ginistinag (XMT-2056) / Mersana, GSK |
| Recruiting | 1 | 162 | US | XMT-2056 | Mersana Therapeutics | HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer | 04/27 | 04/27 | | |
| emiltatug ledadotin (XMT-1660) / Mersana |
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors |
|
|
| Recruiting | 1 | 319 | US | XMT-1660 | Mersana Therapeutics | Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma | 12/26 | 05/27 | | |
| XMT-2068 / Mersana |
| No trials found |
| XMT-2175 / Mersana |
| No trials found |
| Undisclosed ADC therapeutic / Mersana, J&J |
| No trials found |
